Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

Barclays analyst Christopher Pasquale has initiated coverage on Edwards Lifesciences (NYSE: EW) with an Overweight rating. The firm has set a price target of $110 for the stock.